Briacell Therapeutics
BCTX
25 hedge funds and large institutions have $379K invested in Briacell Therapeutics in 2024 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 6 increasing their positions, 6 reducing their positions, and 4 closing their positions.
2,900% more call options, than puts
Call options by funds: $90K | Put options by funds: $3K
100% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 4
19% more funds holding
Funds holding: 21 → 25 (+4)
0% more ownership
Funds ownership: 0.01% → 0.01% (+0%)
0% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 6
30% less capital invested
Capital invested by funds: $538K → $379K (-$159K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CF
Cantor Fitzgerald
New York
|
+$44.7K |
| 2 |
VF
Virtu Financial
New York
|
+$38.8K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$31K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.2K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$24K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
STA
Summit Trail Advisors
New York
|
-$43.4K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$32.8K |
| 3 |
HF
HRT Financial
New York
|
-$29K |
| 4 |
CWP
Concord Wealth Partners
Abingdon,
Virginia
|
-$7.31K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$5K |
BCTX Hedge Fund Activity: Q4 2024 in Review
25 of the 7,593 institutional investors tracked by Wall St. Rank reported a position in Briacell Therapeutics (BCTX) for Q4 2024, worth a combined $379K — down 30% from $538K a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new BCTX positions and 4 closed out — a net gain of 4 holders — while 6 added to existing stakes and 6 trimmed.
The largest buyer was Cantor Fitzgerald, opening a new position worth an estimated $44.7K. The largest seller was Summit Trail Advisors, exiting entirely with an estimated $43.4K sold.
- 25 institutional investors held Briacell Therapeutics (BCTX) as of Q4 2024, up from 21 in Q3 2024.
- Funds reported $379K of Briacell Therapeutics stock for Q4 2024, down 30% quarter-over-quarter.
- 8 funds opened new Briacell Therapeutics positions in Q4 2024 and 4 closed out, a net change of +4 holders.
- The largest Briacell Therapeutics buyer in Q4 2024 was Cantor Fitzgerald, an estimated $44.7K added.
- The largest Briacell Therapeutics seller in Q4 2024 was Summit Trail Advisors, an estimated $43.4K sold.
Based on aggregated 13F filings for Q4 2024.